Although these are not head-to-head comparisons, PRRT for thyroid cancer seems to have comparable ORRs to PRRT in NETs, and while the ORRs are better with TKIs or with selective RET inhibitors, PRRT seems to have a better safety profile compared to these systemic therapies. The gene discussed is RET; the disease is thyroid cancer.